Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS

KROS Stock Annual Income Statement. Download in Excel

Keros Therapeutics Inc. logo

Keros Therapeutics Inc.

Sector: Manufacturing   

Industry: Pharmaceutical Preparation Manufacturing

53.68
 
USD
  
0.75
  
(1.42%)
Previous close: 52.93  Open: 52.68  Bid: 49.86  Ask: 57.27
52 week range    
27.02   
   73.00
Mkt Cap: 1,793 M  Avg Vol (90 Days): 364,443
Peers   
OTIC / 
OTLC / 
OVAT-CA / 
Last updated: Friday 6th September 2024

Stock Rankings

66
MarketXLS Rank
60
Value
84
Technical
55
Quality
How are these ranks calculated?
Ad slot not ready
Search for a stock

Financials

KROS Income Statement

Annual
Invalid dateDec-20Dec-21Dec-22Dec-23
AccruedPreferredStockDividends45 M59 M105 M153 M
Basic EPS from continuing operations-2.93-2.52-4.15-5.2
Basic EPS total-2.93-2.52-4.15-5.2
Basic weighted shares outstanding16 M23 M25 M29 M
Depreciation300000.0400000.0700000.0800000.0
DepreciationAndAmortization300000.0400000.0700000.0800000.0
Diluted EPS total-2.93-2.52-4.15-5.2
Diluted normalized net income/share-2.52-4.15-5.2
Diluted weighted shares outstanding16 M23 M25 M29 M
GeneralAndAdministrativeExpense13 M21 M28 M35 M
Gross operating profit20 M151000.0
Income before tax-46 M-57 M-105 M-153 M
Income taxes-172000.02 M
Interest income-6000.0
InterestExpenseNonOperating6000.04000.01000.0
MiscOtherSpecialCharges3 M-356000.06 M2 M
Net income from total operations-45 M-59 M-105 M-153 M
NetIncomeCommonStockholders-45 M-59 M-105 M-153 M
NetIncomeContinuousOperations-45 M-59 M-105 M-153 M
NetNonOperatingInterestIncomeExpense-6000.0-4000.0-1000.0
Operating income-47 M-56 M-115 M-170 M
Operating income before depreciation (EBITDA)-45 M-56 M-104 M-152 M
OperatingExpense47 M76 M115 M170 M
Other income net-1 M356000.0-6 M-2 M
Other special charges-4 M-15 M
OtherGandA13 M21 M28 M35 M
OtherOperatingExpenses468000.0600000.02 M4 M
OtherunderPreferredStockDividend45 M59 M105 M153 M
PreferredStockDividends45 M59 M105 M153 M
Research & development expense34 M55 M87 M135 M
ResearchExpense34 M55 M87 M135 M
Selling Gen & administrative expense13 M21 M28 M35 M
Special income/charges4 M15 M
Total Income available for interest expense (EBIT)-46 M-57 M-105 M-153 M
Total common shares outstanding23 M29 M36 M
Total net income-45 M-59 M-105 M-153 M
Total ordinary shares36 M36 M36 M36 M
Total revenues20 M151000.0
TotalExpenses47 M76 M115 M170 M
TotalRevenue20 M151000.0
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University